AKTX on Virtual Investor "What This Means" Highlighting its Granted India Patent: June 25, 2025
For the segment, Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed the Company’s recently issued India Patent No. 562,919 titled, “Thailanstatin Analogs,” covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.
▶︎
Akari CEO Corner: 2025 Progress and Path to Clinical Transition In 2026 - January 9, 2026
▶︎
Akari on Virtual Investor “What This Means” - December 18, 2025
▶︎
Princess Of Boogie Woogie Delights Everyone
▶︎
The UNTHINKABLE is About to Happen to SpaceX Stock
▶︎
Welcome to hell: Inside the Colorado supermax prison
▶︎
How US Air Force B 52 Pilot Performed an Emergency Takeoff at Full Speed
▶︎
Akari CEO Corner Highlighting its Strategic Progress and Path to the Clinical - March 13, 2026
▶︎
Akari Virtual Investor “What This Means” Discussing its Expanded ADC Pipeline - Feb. 11, 2026
▶︎
"Most People Don't Realize What Trump Just SIGNED Away at Versailles!" | Bill Clinton
▶︎
Why birth rates are falling everywhere all at once | FT
▶︎
Akari in Virtual Investor “What This Means” Discussing Partnership with WuXi XDC - April 9, 2026
▶︎
INSIDE THE G7 BREAK | Meloni’s BODY LANGUAGE toward Trump STEALS THE SHOW
▶︎
If You Own Silver, Watch This Before June 16 (Here’s Why)
▶︎
Learn From Proficiency: Here’s How Today’s Market Wizards Made Their Fortunes | Investing With IBD
▶︎
The FULL VIDEO of Trump they didn’t want released
▶︎
Akari Discusses Breakthrough Potential of AKTX-101 and Novel ADC Platform - May 28, 2026
▶︎
1 IN A MILLION MOMENTS IN SPORTS !
▶︎
Introducing the American AI Sovereign Wealth Fund Act
▶︎
Nobody Breaks Celebrities Like Rowan Atkinson
▶︎